Ionis Pharmaceuticals has been invited to participate in new Medicaid arrangements, coinciding with Donald Trump's promise of globally cheapest drug prices.
1 report, 1 independent
Updated Jun 30
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Ionis Pharmaceuticals has been invited to participate in new Medicaid arrangements, coinciding with Donald Trump's promise of globally cheapest drug prices.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Ionis Pharmaceuticals
American pharmaceutical company
-
Medicare
US federal health insurance
Related events
- Tariffs are introducing uncertainty into the drug market structure.
- Slotkin argues Medicare should negotiate drug prices while criticizing Trump's proposed tariffs on generic drugs.
- Administration proposes a rule to manage Medicare drug costs, reported by the Associated Press.
- US drug pricing policy from the Trump era was compared to Japanese market practices, affecting Medicare and involving Japanese medical professionals.
- CMS introduced the Medicare drug price negotiation program, and companies are facing challenges regarding pricing and market access.